Clinical trial · Interventional
Binaural Sound for Remimazolam Maintenance
The Effect of Intraoperative Binaural Sound on Remifentanil Dose Required for General Anesthesia Using Remimazolam: a Randomized, Placebo-controlled Trial
NCT06497283CI-TRIAL-00079675unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It is important to decrease the remifentanil dose for general anesthesia maintenance when using remimazolam. We will evaluate the effect of binaural sound on general anesthesia maintenance with remimazolam infusion.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| General Anesthesia | — | UNRESOLVED | — |
| Prostate Cancer Stage | Myofibroma | PROBABILISTIC | 0.70 |
| Uterine Myoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Binaural sound | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- I (Binaural)
- description
- Binaural sound using earphone will be applied.
- interventionNames
- Procedure: Binaural sound
- type
- PLACEBO_COMPARATOR
- label
- II (Placebo)
- description
- Only headphone without sound will be applied.
- interventionNames
- Procedure: Binaural sound
Primary outcomes (1)
- measure
- Intraoperative remifentanil dose
- timeFrame
- At anesthesia day 0
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients scheduled for general anesthesia 2. Patients aged 20-60 3. Patients with American Society of Anesthesiologist physical status classification 1-2 4. Patients with ideal body weight 50-80 kg Exclusion Criteria: 1. Patients with hearing disability 2. Patients using opioids or sedatives in 1 week 3. Patients who are dependent for alcoholics or drugs 4. Patients with hypersensitivities to remimazolam or remifentanil 5. Patients with arrhythmia, cardiovascular disease, heart failure, or hypovolemia 6. Patients with liver failure
References
Publications (0)
Data not yet available
No reference posted for this study.